Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
Add more filters










Publication year range
1.
Drug Dev Res ; 78(8): 411-419, 2017 12.
Article in English | MEDLINE | ID: mdl-28921601

ABSTRACT

Preclinical Research Δ9 -Tetrahydrocannabinol (THC) is a hydrophobic compound that has a potent antinociceptive effect in animals after intrathecal (IT) or intracerebroventricular (ICV) administration. The lack of a suitable solvent precludes its IT administration in humans. 2-Hydroxypropyl-ß-cyclodextrin (HPßCD) increases the water solubility of hydrophobic drugs and is approved for IT administration in humans. To investigate whether HPßCD might be a suitable carrier for ICV administration of THC in rats, two formulations containing THC complexed with HPßCD (30 and 135 µg of THC per animal) and vehicle were administered to Wistar rats. The antinociceptive effect (using the tail flick test), locomotor activity, and body temperature were evaluated. ICV injection of 135 µg of THC/HPßCD complex increased tail flick latency, reduced locomotor activity, and had a dual effect on body temperature. The 30 µg THC/HPßCD formulation only produced a hyperthermic effect. All animals appeared healthy, with no difference between the groups. These results were similar to those obtained in other preclinical studies in which THC was administered centrally using solvents that are unsuitable for IT administration in humans because of their toxicity. Our findings suggest that HPßCD may be a useful carrier for IT administration of THC in humans. Drug Dev Res 78 : 411-419, 2017. © 2017 Wiley Periodicals, Inc.


Subject(s)
2-Hydroxypropyl-beta-cyclodextrin/chemistry , Analgesics, Non-Narcotic/administration & dosage , Body Temperature/drug effects , Dronabinol/administration & dosage , Locomotion/drug effects , 2-Hydroxypropyl-beta-cyclodextrin/pharmacology , Analgesics, Non-Narcotic/chemistry , Analgesics, Non-Narcotic/pharmacology , Animals , Dronabinol/chemistry , Dronabinol/pharmacology , Drug Carriers , Drug Compounding , Drug Evaluation, Preclinical , Injections, Spinal , Male , Rats , Rats, Wistar , Solubility
2.
Rheumatol Int ; 34(8): 1047-52, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24509894

ABSTRACT

Fibromyalgia is a pain disorder associated with frequent comorbid mood, anxiety, and sleep disorders. Despite the frequent use of a complex, poly-drug pharmacotherapy, treatment for fibromyalgia is of limited efficacy. Oxytocin has been reported to reduce the severity of pain, anxiety, and depression, and improve the quality of sleep, suggesting that it may be useful to treat fibromyalgia. To evaluate this hypothesis, 14 women affected by fibromyalgia and comorbid disorders, assuming a complex pharmacotherapy, were enrolled in a double-blind, crossover, randomized trial to receive oxytocin and placebo nasal spray daily for 3 weeks for each treatment. Order of treatment (placebo-oxytocin or oxytocin-placebo) was randomly assigned. Patients were visited once a week. At each visit, the following instruments were administered: an adverse drug reaction record card, Visual Analog Scale of Pain Intensity, Spielberger State Anxiety Inventory, Zung Self-rating Depression Scale, and SF-12. Women self-registered painkiller assumption, pain severity, and quality of sleep in a diary. Unlikely, oxytocin nasal spray (80 IU a day) did not induce positive therapeutic effects but resulted to be safe, devoid of toxicity, and easy to handle.


Subject(s)
Fibromyalgia/drug therapy , Musculoskeletal Pain/drug therapy , Oxytocin/administration & dosage , Administration, Intranasal , Aerosols , Anxiety/drug therapy , Anxiety/psychology , Comorbidity , Cross-Over Studies , Depression/drug therapy , Depression/psychology , Double-Blind Method , Female , Fibromyalgia/diagnosis , Fibromyalgia/physiopathology , Fibromyalgia/psychology , Humans , Middle Aged , Musculoskeletal Pain/diagnosis , Musculoskeletal Pain/physiopathology , Musculoskeletal Pain/psychology , Oxytocin/adverse effects , Pain Measurement , Psychiatric Status Rating Scales , Quality of Life , Sleep/drug effects , Surveys and Questionnaires , Time Factors , Treatment Outcome
3.
Immunobiology ; 218(7): 995-1004, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23332216

ABSTRACT

In this study we wanted to analyse the pattern of the immune response to the Parietaria major allergen Par j 1 in freshly purified peripheral blood mononuclear cell (PBMC) from healthy subjects. We observed that Par j 1 was capable of inducing IFN-γ production by CD3⁻ and CD16⁺/CD56⁺ cells exclusively in healthy individuals. Furthermore, a multiparametric analysis allowed us a better definition of two IFN-γ-Par j 1 specific populations (IFN-γ(dim) and IFN-γ(high)) characterized by the presence of different proportions of NKT and NK cells. We also identified the concomitant presence of a subset of IL-10⁺ NK cells. Moreover, CFSE staining showed that the Par j 1 preferentially induced the proliferation of CD3⁻/CD56⁺/CD335⁺ cells. Finally, a subset of CD4⁺/CD25⁺/FoxP3⁺/IL-10⁻ T cells was identified. The result of this pilot study suggest that during a tolerogenic response, the major allergen of the Parietaria pollen works as an activator of both the innate and the adaptive human immune system.


Subject(s)
Adaptive Immunity , Allergens/pharmacology , Immunity, Innate , Killer Cells, Natural/drug effects , Natural Killer T-Cells/drug effects , Parietaria/immunology , Plant Proteins/pharmacology , Adult , Allergens/biosynthesis , Allergens/genetics , Antigens, CD/genetics , Antigens, CD/immunology , Cells, Cultured , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/immunology , Gene Expression/drug effects , Humans , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukin-10/genetics , Interleukin-10/immunology , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Natural Killer T-Cells/cytology , Natural Killer T-Cells/immunology , Plant Proteins/biosynthesis , Plant Proteins/genetics , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology
4.
Neuroscience ; 147(1): 197-206, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17507169

ABSTRACT

[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection. This effect is mediated by the release of glutamic acid, which in turn activates central oxytocinergic neurons mediating penile erection. Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. As GABAergic synapses in the PVN impinge directly on oxytocinergic neurons or on excitatory glutamatergic synapses, which also impinge on oxytocinergic neurons, these results suggest that the blockade of CB1 receptors decreases GABA release in the PVN, increasing in turn glutamatergic neurotransmission to activate oxytocinergic neurons mediating penile erection. Autoradiography studies with [(3)H](-)-CP 55,940 show that chronic treatment with SR 141716A for 15 days twice daily (1 mg/kg i.p.) significantly increases the density of CB1 receptors in the PVN. This increase occurs concomitantly with an almost twofold increase in the pro-erectile effect of SR 141716A injected into the PVN as compared with control rats. The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of CB1 receptors by SR 141716A increases the density of these receptors in the PVN. This increase is related to an enhanced pro-erectile effect of SR 141716A, which is still present 3 days after the end of the chronic treatment.


Subject(s)
Neural Inhibition/drug effects , Paraventricular Hypothalamic Nucleus/metabolism , Penile Erection/physiology , Receptor, Cannabinoid, CB1/metabolism , Animals , Glutamic Acid/metabolism , Immunohistochemistry , Male , Microinjections , Neural Inhibition/physiology , Neurotransmitter Agents/administration & dosage , Oxytocin/metabolism , Paraventricular Hypothalamic Nucleus/drug effects , Paraventricular Hypothalamic Nucleus/physiology , Penile Erection/drug effects , Piperidines/administration & dosage , Pyrazoles/administration & dosage , Rats , Rats, Sprague-Dawley , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Rimonabant , Sexual Behavior, Animal/drug effects , Sexual Behavior, Animal/physiology , Signal Transduction/physiology , Tissue Distribution , gamma-Aminobutyric Acid/metabolism
5.
J Endocrinol Invest ; 26(3 Suppl): 20-2, 2003.
Article in English | MEDLINE | ID: mdl-12834016

ABSTRACT

The cycle of sexual activity in men and women occurs in 4 phases--excitation, plateau, orgasm, resolution--which are guided by sexual desire. Male sexual activity is characterized by erection, seminal emission and ejaculation (orgasm), whereas female sexual activity is characterized by vaginal lubrication, erection of the clitoris and orgasm. These responses are under the control of numerous central and peripheral neural systems. The central supraspinal systems are mainly localized in the limbic system (olfactory nuclei, medial preoptic area, nucleus accumbens, amygdala, hippocampus etc.), in the hypothalamus and its nuclei (paraventricular and ventromedial nuclei). Neural information travels through the brain stem, the medulla oblongata, the spinal cord and the autonomous nervous system to the genital apparatus. While we have very detailed knowledge of the neural mechanism, which controls the function of the male and female genital organs, in particular those mediating erection, very little is known of the central mechanism involved. Nevertheless, several neurotransmitters and neuropeptides, such as dopamine, glutamic acid, nitric oxide, oxytocin, ACTH-MSH peptides, are known to facilitate sexual function, while serotonin, gamma-aminobutyric acid (GABA) and opioid peptides reduce it. At the level of the paraventricular nucleus a group of oxytocinergic neurons projecting to extra-hypothalamic brain areas, including the spinal cord, have been identified, which facilitate erectile function and copulation when activated and reduce both when inhibited. Although the majority of results, which have clarified the mechanisms involved, have been performed in males, it is believed that similar mechanisms are also operative in females.


Subject(s)
Nervous System Physiological Phenomena , Sexual Behavior/physiology , Central Nervous System/physiology , Genitalia/innervation , Humans
6.
Curr Drug Targets ; 4(1): 55-66, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12528990

ABSTRACT

A group of oxytocinergic neurons originating in the paraventricular nucleus of the hypothalamus and projecting to extrahypothalamic brain areas (e.g. hippocampus, medulla oblongata and spinal cord) control penile erection. Activation of these neurons by dopamine and dopamine agonists, excitatory amino acids (N-methyl-D-aspartic acid) or oxytocin itself, or by electrical stimulation leads to penile erection, while their inhibition by GABA and GABA agonists or by opioid peptides and opiate-like drugs inhibits this sexual response. The activation of oxytocinergic neurons in the paraventricular nucleus by dopamine, oxytocin and excitatory amino acids is apparently secondary to the activation of nitric oxide (NO) synthase. NO in turn activates, by a mechanism that is as yet unidentified, the release of oxytocin from oxytocinergic neurons in extrahypothalamic brain areas. Several peptide analogues of hexarelin, a growth hormone releasing peptide, also induce penile erection when injected into the paraventricular nucleus and, to a lesser extent, systemically, apparently by acting on a specific receptor to activate oxytocinergic neurons as shown for the above drugs and oxytocin. Paraventricular oxytocinergic neurons and mechanisms similar to those reported above are also involved in the expression of penile erection in physiological contexts, namely when penile erection is induced in the male by the presence of an inaccessible receptive female, which is considered a model for psychogenic impotence in man, as well as during copulation. These findings show that paraventricular oxytocinergic neurons projecting to extra-hypothalamic brain areas and to the spinal cord are a likely target for the treatment of erectile dysfunction of central origin.


Subject(s)
Erectile Dysfunction/drug therapy , Neurons/metabolism , Neurotransmitter Agents/physiology , Oxytocin/metabolism , Animals , Dopamine Agonists/pharmacology , Erectile Dysfunction/physiopathology , Erectile Dysfunction/psychology , Excitatory Amino Acid Agonists/pharmacology , GABA Agonists/pharmacology , Growth Substances/metabolism , Humans , Male , Narcotics/pharmacology , Neurons/physiology , Nitric Oxide/physiology , Oxytocin/pharmacology , Paraventricular Hypothalamic Nucleus/drug effects , Paraventricular Hypothalamic Nucleus/physiology
7.
Neurosci Lett ; 314(3): 123-6, 2001 Nov 16.
Article in English | MEDLINE | ID: mdl-11704299

ABSTRACT

Male rats show 4-6 penile erection episodes when put in the presence of an inaccessible receptive female. These non-contact penile erections were reduced dose-dependently by muscimol, a gamma aminobutyric acid (GABA)(A) receptor agonist, when given into the paraventricular nucleus of the hypothalamus (0.1, 0.5, 1 and 2 microg). In contrast, baclofen, a GABA(B) receptor agonist (2 microg) was ineffective. Muscimol reduction of non-contact penile erections was not seen when male rats were pretreated with bicuculline methiodide (2 microg) given 5 min before muscimol into the paraventricular nucleus. Since muscimol injected into the paraventricular nucleus also prevents penile erection induced by drugs (e.g. apomorphine, oxytocin or N-methyl-D-aspartic acid), the present results show that an increased GABAergic activity in the paraventricular nucleus can impair the expression of penile erection induced not only by drugs but also by sexual physiological stimuli.


Subject(s)
Copulation/physiology , GABA Agonists/pharmacology , Neurons/metabolism , Paraventricular Hypothalamic Nucleus/metabolism , Penile Erection/physiology , Receptors, GABA-A/metabolism , gamma-Aminobutyric Acid/metabolism , Animals , Baclofen/pharmacology , Copulation/drug effects , Dose-Response Relationship, Drug , Female , GABA-A Receptor Agonists , GABA-B Receptor Agonists , Male , Microinjections , Muscimol/pharmacology , Neural Inhibition/drug effects , Neural Inhibition/physiology , Neural Pathways/drug effects , Neural Pathways/physiology , Neurons/cytology , Neurons/drug effects , Paraventricular Hypothalamic Nucleus/cytology , Paraventricular Hypothalamic Nucleus/drug effects , Penile Erection/drug effects , Rats , Rats, Sprague-Dawley , Receptors, GABA-B/metabolism , Synaptic Transmission/drug effects , Synaptic Transmission/physiology
8.
Neuropharmacology ; 41(2): 254-62, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11489462

ABSTRACT

The effect of EP 91073, EP 51389, EP 70555 and EP 51216, peptide analogues of the growth hormone releasing peptide hexarelin, on penile erection induced by EP 80661 or EP 60761 injected into the paraventricular nucleus of the hypothalamus, was studied in male rats. Of the above peptides only EP 91073 (0.2-1 microg) was found capable of reducing penile erection induced by EP 80661 or EP 60761, when given into the paraventricular nucleus. Despite its ability to prevent EP peptide-induced penile erection, EP 91073 (1 microg) was unable to prevent penile erection induced by the dopamine receptor agonist apomorphine (50 ng), oxytocin (30 ng) and N-methyl-D-aspartic acid (50 ng), when given into the paraventricular nucleus 10 min prior to the above substances. The EP 91073-induced prevention of penile erection occurred with a reduction in the increase in nitric oxide production that occurs in the paraventricular nucleus concomitant to penile erection induced by EP 80661 and EP 60761, as measured by intracerebral vertical microdialysis. The present results are in line with the hypothesis that EP 80661 and EP 60761 induce penile erection by activating specific receptors in the paraventricular nucleus, located possibly in oxytocinergic neurons mediating penile erection, and show that EP 91073 acts as an antagonist of these EP peptide receptors mediating penile erection.


Subject(s)
Oligopeptides/pharmacology , Paraventricular Hypothalamic Nucleus/drug effects , Penile Erection/drug effects , Receptors, Peptide/physiology , Animals , Male , Nitric Oxide/biosynthesis , Oligopeptides/chemistry , Paraventricular Hypothalamic Nucleus/metabolism , Penile Erection/physiology , Rats , Rats, Sprague-Dawley , Receptors, Peptide/biosynthesis
9.
Eur J Pharmacol ; 411(3): 305-10, 2001 Jan 12.
Article in English | MEDLINE | ID: mdl-11164389

ABSTRACT

The effect of GAB-D-Trp(2-Me)-D-Trp(2-Me)-LysNH(2) (EP 80661), GAB-D-Trp(2-Me)-D-Trp(2-Me)-D-Trp(2-Me)-LysNH(2) (EP 60761), GAB-D-Trp(2-Me)-LysNH(2) (EP 91071) and GAB-D-Trp(2-Me)-D-beta Nal-Phe-LysNH(2) (EP 50885), four hexarelin peptide analogues that induce penile erection when injected into the paraventricular nucleus of the hypothalamus of male rats, on the concentration of NO(2)(-) and NO(3)(-) in the paraventricular dialysate was studied in male rats. EP peptides (1 microg) induced penile erection and increased the concentration of NO(2)(-) and NO(3)(-) in the paraventricular dialysate. In contrast, hexarelin (1 microg) was ineffective on either penile erection or paraventricular NO(2)(-) and NO(3)(-). EP peptide-induced penile erection was prevented by the nitric oxide synthase inhibitor N(G)-nitro-l-arginine methylester given into the paraventricular nucleus (20 microg), which also reduced the concomitant increase of NO(2)(-) and NO(3)(-) concentration in the paraventricular dialysate. In contrast, the oxytocin receptor antagonist [d(CH(2))(5)Tyr(Me)(2)-Orn(8)]vasotocin (1 microg) given into the paraventricular nucleus, was ineffective on penile erection and on the NO(2)(-) and NO(3)(-) increase induced by EP peptides, despite its ability to prevent the sexual response induced by the above peptides when given into the lateral ventricles. The present results show that EP peptides induce penile erection by activating nitric oxide synthase in the paraventricular nucleus of the hypothalamus, possibly in the cell bodies of oxytocinergic neurons that control penile erection.


Subject(s)
Growth Substances/pharmacology , Nitric Oxide/physiology , Oligopeptides/pharmacology , Paraventricular Hypothalamic Nucleus/physiology , Penile Erection/drug effects , Animals , Behavior, Animal/drug effects , Enzyme Inhibitors/pharmacology , Growth Substances/administration & dosage , Male , Microdialysis , Microinjections , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase Type I , Oligopeptides/administration & dosage , Paraventricular Hypothalamic Nucleus/metabolism , Rats , Rats, Sprague-Dawley
10.
Eur J Pharmacol ; 404(1-2): 137-43, 2000 Sep 15.
Article in English | MEDLINE | ID: mdl-10980272

ABSTRACT

The effect of hexarelin and four related peptide analogues, EP 40904, EP 40737, EP 50885 and EP 60761, injected into the paraventricular nucleus of the hypothalamus of male rats in doses between 2 and 2000 ng on spontaneous penile erection was studied. Of these peptides, EP 60761 and EP 50885, but not hexarelin, EP 40904 or EP 40737, increased dose-dependently the number of spontaneous penile erections. EP 60761 was active already at the dose of 20 ng, which induced the sexual response in 70% of the treated rats. The maximal response was induced by 200 ng of the peptide. EP 50885 was less potent than EP 60761, with 1000 ng being the minimal effective dose and 2000 ng as the dose required to induce the maximal response. At the doses used, both peptides also increased slightly the number of spontaneous yawning episodes. EP 60761- and EP 50885-induced penile erection was prevented by the oxytocin receptor antagonist [d(CH(2))(5)Tyr(Me)(2)-Orn(8)]vasotocin (0.1-1 microg) given intracerebroventricularly (i.c.v.), but not into the paraventricular nucleus (0.1-1 microg), by the competitive nitric oxide (NO) inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) given either into the paraventricular nucleus (10-20 microg) or i.c.v. (75-150 microg), by the N-type Ca(2+) channel blocker omega-conotoxin-GVIA (2-5 ng) or by the opiate morphine (1-10 microg), but not by the dopamine receptor antagonist (Z)-4-[3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]-1-p ipe razine-ethanol (cis-flupenthixol) (10 microg) or by the N-methyl-D-aspartic acid (NMDA) receptor antagonist (5R, 10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine ((+)-MK-801) (1 microg), all given into the paraventricular nucleus before either peptide. The present results show that EP 60761 and EP 50885 induced penile erection by increasing central oxytocin transmission, possibly by activating NO synthase in the cell bodies of oxytocinergic neurons located in the paraventricular nucleus that control penile erection.


Subject(s)
Oligopeptides/pharmacology , Paraventricular Hypothalamic Nucleus/drug effects , Penile Erection/drug effects , Animals , Calcium Channel Blockers/pharmacology , Dizocilpine Maleate/pharmacology , Dopamine Antagonists/pharmacology , Drug Interactions , Enzyme Inhibitors/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Flupenthixol/pharmacology , Male , Morphine/pharmacology , NG-Nitroarginine Methyl Ester/pharmacology , Oligopeptides/chemistry , Paraventricular Hypothalamic Nucleus/physiology , Peptide Fragments/pharmacology , Rats , Rats, Sprague-Dawley , Vasotocin/pharmacology , omega-Conotoxin GVIA/pharmacology
11.
Behav Neurosci ; 114(4): 849-57, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10959543

ABSTRACT

In male rats, noncontact erections occur concomitantly with an increase in NO2- and NO3- in the paraventricular nucleus of the hypothalamus (PVN). In the present study, both responses were reduced by the blockade of PVN excitatory amino acid receptors by dizocilpine, (+)-MK-801(1 and 5 microg), but not by 6-cyano-7-nitro-quinoxaline-2,3-dione (5 microg) or (+)-2-amino-4-phosphono-butanoic acid (5 microg). Also ineffective when injected into the PVN were the dopamine antagonists SCH 23390 (5 microg), S(+)-raclopride (10 microg), and cis-flupenthixol (10 microg), and the oxytocin antagonist d(CH2)5Tyr(Me)2-Om8-vasotocin (1 microg). However, when the last was given into the lateral ventricles, it reduced noncontact erections without modifying NO2- and NO3- increases. These results suggest that excitatory amino acid transmission increases in the PVN during noncontact erections. This may contribute to increased NO production in the PVN, and it may activate oxytocin neurons mediating this sexual response.


Subject(s)
Dopamine Antagonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Nitric Oxide/metabolism , Paraventricular Hypothalamic Nucleus/drug effects , Penile Erection/drug effects , Receptors, Oxytocin/antagonists & inhibitors , Animals , Brain Mapping , Dose-Response Relationship, Drug , Injections, Intraventricular , Male , Microinjections , Neurons/drug effects , Rats , Rats, Sprague-Dawley
12.
Brain Res Bull ; 51(5): 425-31, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10715564

ABSTRACT

The effect of adrenocorticotropin (ACTH)(1-24) and alpha-melanocyte stimulating hormone (alpha-MSH) on grooming, stretching, yawning and penile erection was studied after injection into different brain areas. Both peptides induce the above responses when injected into the hypothalamic periventricular region of the third ventricle. This region includes the paraventricular nucleus, the dorsomedial nucleus, the ventromedial nucleus and the anterior hypothalamic area. The minimal effective dose of both peptides was 0.5 microg and the maximal effect was seen with 2 microg, the highest dose tested. Irrespective of the injection site, grooming started 5-7 min after injection of either peptide, while stretching, yawning and penile erection started only after 15-35 min and lasted for 90-120 min. In contrast both peptides were ineffective when injected into the preoptic area, the caudate nucleus or the CA1 field of the hippocampus. Grooming, stretching and yawning, but not penile erection, were prevented by cyclic[AcCys(11), D-Nal(14), Cys(18), AspNH(2)(22)]-beta-MSH (11-22) (HS014), a selective melanocortin 4 receptor antagonist, injected into the same periventricular area 10 min before of ACTH(1-24) or alpha-MSH. The results show that ACTH(1-24) and alpha-MSH act in the hypothalamic periventricular region to induce the above responses and that grooming, stretching and yawning, but not penile erection, are mediated by melanocortin 4 receptors.


Subject(s)
Brain Mapping , Cosyntropin/pharmacology , Grooming/physiology , Penile Erection/physiology , Receptors, Corticotropin/physiology , Yawning/physiology , alpha-MSH/pharmacology , Animals , Male , Microinjections , Peptides, Cyclic/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Melanocortin
13.
Neuroendocrinology ; 72(6): 327-32, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11146415

ABSTRACT

We have previously reported that hexarelin and some of its analogs, including EP 50885, stimulated GH secretion and feeding after systemic administration in the rat, whereas EP 40904 selectively stimulated food intake and EP 40737 only GH release. The precise mechanism of growth hormone-releasing peptides (GHRPs) actions is still unclear, but the integrity of the arcuate nucleus of the hypothalamus (ARC) appears crucial for their endocrine effects. To better characterize the site(s) and mechanisms(s) of the orexigenic action of GHRPs, we have investigated their effects after infusion into the arcuate, paraventricular, ventromedial and medial preoptic areas of the hypothalamus. Food intake was measured for 60 min following injection of the test compound (2 microg/rat). Hexarelin, EP 40904 and EP 50885 had significant orexigenic effects after injection into the ARC. A specific NPY antagonist significantly inhibited the effect of hexarelin, whereas a GHRH antagonist was ineffective. In the paraventricular nucleus, only EP 50885 stimulated feeding, whereas all peptides were ineffective in the ventromedial nucleus and medial preoptic area. Taken altogether, these results demonstrate that GHRPs are endowed with site-specific orexigenic actions and that endogenous NPY, but not GHRH, mediates these effects. The additional orexigenic action of EP 50885 in the paraventricular nucleus suggests the existence of a GHRP receptor subtype different from the already cloned one.


Subject(s)
Hypothalamus/drug effects , Hypothalamus/metabolism , Oligopeptides/pharmacology , Receptors, Somatotropin/metabolism , Sermorelin/analogs & derivatives , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Arcuate Nucleus of Hypothalamus/metabolism , Eating/drug effects , Eating/physiology , Growth Hormone-Releasing Hormone/antagonists & inhibitors , Growth Hormone-Releasing Hormone/metabolism , Hormone Antagonists/pharmacology , Injections, Intraventricular , Male , Neuropeptide Y/antagonists & inhibitors , Neuropeptide Y/metabolism , Paraventricular Hypothalamic Nucleus/drug effects , Paraventricular Hypothalamic Nucleus/metabolism , Preoptic Area/drug effects , Preoptic Area/metabolism , Rats , Rats, Sprague-Dawley , Sermorelin/pharmacology , Ventromedial Hypothalamic Nucleus/drug effects , Ventromedial Hypothalamic Nucleus/metabolism
14.
Int J Impot Res ; 12(5): 255-62, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11424962

ABSTRACT

The effect of 10 peptides structurally related to the growth hormone (GH) releasing peptide hexarelin, injected into the paraventricular nucleus of the hypothalamus (PVN), on penile erection was studied in male rats. Six out of the 10 peptides tested induced penile erection in a dose-dependent manner. Among them, the most potent were EP 80661, EP 60761 and EP 91072, which were active at doses of 20-200 ng. The potency of these peptides in inducing penile erection is comparable to that of apomorphine, oxytocin and N-methyl-D-aspartic acid similarly injected into the PVN. Other peptides found active were EP 50885, EP 90101 and EP 91071, which induced penile erection at doses of 200-2000 ng. In contrast, EP 51322, EP 70555, EP 51216 and EP 91073 were inactive, as were hexarelin, EP 40904 and EP 40737 in a previous study. The majority of EP peptides found active when injected into the PVN induced penile erection, although to a lesser extent, also when given systemically (endovenously). The proerectile effect of EP peptides was prevented by the oxytocin receptor antagonist [d(CH2)5 Tyr(Me)2-Orn8]-vasotocin given into the lateral ventricles but not into the PVN, by the nitric oxide (NO) synthase inhibitor N(G)-nitro-1-arginine methyl ester given either into the lateral ventricles or into the PVN, by the N-type Ca2+ channel blocker omega-conotoxin GVIA and by morphine, but not by the dopamine receptor antagonist cis-flupenthixol or by the N-methyl-D-aspartic acid receptor antagonist dizolcipine, given into the PVN. As the structure-activity relationship of EP peptides for proerectile activity is different from those of other biological actions of these compounds, ie for GH release and eating behaviour, the present results suggest that EP peptides induce penile erection by acting on specific hypothalamic receptor sites that activate paraventricular oxytocinergic neurons projecting to extrahypothalamic brain areas that mediate this sexual function by a mechanism similar to that of dopamine receptor agonists, oxytocin and N-methyl-D-aspartic acid.


Subject(s)
Apomorphine/pharmacology , Dopamine Agonists/pharmacology , Excitatory Amino Acid Agonists/pharmacology , N-Methylaspartate/pharmacology , Oligopeptides/pharmacology , Oxytocin/pharmacology , Penile Erection/drug effects , Animals , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Feeding Behavior/drug effects , Injections, Intraventricular , Male , Oligopeptides/administration & dosage , Penis/anatomy & histology , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
15.
Eur J Neurosci ; 11(6): 1857-64, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10336653

ABSTRACT

Male rats show four to six penile erection episodes when put in the presence of an inaccessible receptive female for 80 min. These noncontact erections occur concomitantly with an increase in nitric oxide production in the paraventricular nucleus of the hypothalamus. This is shown by the increases in the NO2- and NO3- concentrations in the paraventricular dialysate obtained from these males by in vivo microdialysis. The NO2- concentration increased from 0.75 +/- 0. 10 microm to 2.89 +/- 0.39 microm and that of NO3- from 4.13 +/- 0. 58 microm to 9.5 +/- 1.2 microm. Morphine (0.5, 1 and 5 microg), given unilaterally into the paraventricular nucleus 15 min before the introduction of the receptive female, prevented the NO2- and NO3- increases, and noncontact erections, dose-dependently. In contrast, the kappa opioid receptor agonist U-69 593 (5 microg) was ineffective. The effects of morphine on NO2- and NO3-, and on noncontact erections, were prevented by the opiate receptor antagonist naloxone (10 microg) injected into the paraventricular nucleus 15 min before morphine. The NO2- and NO3- concentrations were also increased in the paraventricular dialysate of male rats during copulation, i.e. when in copula penile erections occurred. As found with noncontact erections, morphine, but not U-69 593, injected into the paraventricular nucleus prevented the NO2- and NO3- increases and impaired copulatory behaviour, and naloxone prevented these responses when given before morphine. Although some diffusion of the opiate to surrounding brain areas cannot be completely ruled out, the present results suggest that morphine acts through mu receptors in the paraventricular nucleus to impair noncontact erections and copulation. These effects of morphine are apparently mediated by a prevention of the increased nitric oxide production that occurs in the paraventricular nucleus of the hypothalamus of male rats during sexual activity.


Subject(s)
Benzeneacetamides , Copulation/drug effects , Copulation/physiology , Morphine/pharmacology , Nitric Oxide/physiology , Paraventricular Hypothalamic Nucleus/physiology , Penile Erection/drug effects , Penile Erection/physiology , Animals , Female , Injections , Male , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Pyrrolidines/pharmacology , Rats , Rats, Sprague-Dawley , Sexual Behavior, Animal/drug effects
16.
Neurosci Lett ; 265(3): 171-4, 1999 Apr 23.
Article in English | MEDLINE | ID: mdl-10327158

ABSTRACT

Male rats show four to six penile erection episodes when put for 80 min in the presence of an inaccessible receptive female. These non-contact penile erections were reduced dose-dependently by d(CH2)5Tyr(Me)2-Orn8-vasotocin, a potent and selective oxytocin receptor antagonist, when given into the lateral ventricles (0.1, 0.5 and 1 microg), but not when given into the paraventricular nucleus of the hypothalamus (0.1 and 1 microg). In contrast, non-contact erections were reduced by N(G)-nitro-L-arginine methyl ester, a competitive inhibitor of nitric oxide synthase, given into the lateral ventricles (50, 100 and 200 microg), or into the paraventricular nucleus (10 and 20 microg). The present results show that central oxytocin is involved in the expression of penile erection induced not only by drugs but also by sexual physiological stimuli.


Subject(s)
Oxytocin/analogs & derivatives , Penile Erection/drug effects , Animals , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Female , Male , Microinjections , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/metabolism , Oxytocin/pharmacology , Paraventricular Hypothalamic Nucleus/drug effects , Paraventricular Hypothalamic Nucleus/physiology , Physical Stimulation , Rats , Rats, Sprague-Dawley , Sexual Behavior, Animal/drug effects
17.
Zhongguo Yao Li Xue Bao ; 20(9): 778-88, 1999 Sep.
Article in English | MEDLINE | ID: mdl-11245084

ABSTRACT

Yawning is a phylogenetically old, stereotyped event that occurs alone or associated with stretching and/or penile erection in humans, in animals from reptiles to birds and mammals, under different conditions. Several neurotransmitters and neuropeptides are involved in its control at the central level. One of these at the level of the paraventricular hypothalamic nucleus (PVHN) is nitric oxide (NO). First, NO synthase inhibitors injected into this hypothalamic nucleus prevent yawning induced by dopamine agonists, oxytocin or N-methyl-D-aspartic acid (NMDA), which induce yawning by activating PVHN oxytocinergic neurons projecting to extra-hypothalamic brain areas. The inhibitory effect of NO synthase inhibitors was not observed when these compounds were given concomitantly with L-arginine, the precursor of NO. Second, dopamine agonists, NMDA and oxytocin given at doses that induce yawning, increase NO production in the PVHN, as determined by in vivo microdialysis. Conversely, the opiate morphine, which prevents yawning induced by dopamine agonists, oxytocin and NMDA, also prevents the increase in the paraventricular NO production induced by these compounds. Third, NO donors, such as nitroglycerin, sodium nitroprusside and hydroxylamine, induce yawning when injected into the PVHN apparently by activating oxytocinergic transmission. Since guanylate cyclase inhibitors and NO scavengers (hemoglobin) injected into the PVHN do not prevent drug-induced yawning, nor 8-Br-cGMP injected into the PVHN induces this behavioral response, it is likely that NO acts as an intracellular rather than an intercellular modulator inside the PVHN oxytocinergic neurons in which NO is formed to facilitate the expression of this phylogenetically old event by guanylate cyclase-independent mechanisms.


Subject(s)
Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide/physiology , Paraventricular Hypothalamic Nucleus/metabolism , Yawning , Animals , Dopamine Agonists/pharmacology , Humans , Morphine/pharmacology , N-Methylaspartate/pharmacology , Nitric Oxide Synthase/metabolism , Oxytocin/pharmacology , Yawning/drug effects , Yawning/physiology
18.
Eur J Pharmacol ; 359(1): 19-26, 1998 Oct 16.
Article in English | MEDLINE | ID: mdl-9831288

ABSTRACT

A dose of apomorphine or oxytocin that induces penile erection and yawning increases nitric oxide production in the paraventricular nucleus of the hypothalamus, as determined by the increase in NO2- and NO3- concentration induced by these substances in the paraventricular dialysate obtained from male rats. All the above responses were prevented by a dose of omega-conotoxin-GVIA as low as 5 ng. This potent inhibitor of N-type Ca2+ channels was injected into the paraventricular nucleus 15 min before apomorphine (50 ng) or oxytocin (10 ng). In contrast, omega-conotoxin was ineffective when the above responses were induced by N-methyl-D-aspartic acid (50 ng). The peptide toxin (5 ng) was also ineffective on the penile erection and yawning induced by the nitric oxide donors sodium nitroprusside (50 microg) or hydroxylamine (50 microg), injected into the paraventricular nucleus. The present results suggest that omega-conotoxin-sensitive Ca2+ channels are involved in the activation of nitric oxide synthase, penile erection and yawning induced by apomorphine and oxytocin, but not by N-methyl-D-aspartic acid, at the paraventricular level.


Subject(s)
Calcium Channel Blockers/pharmacology , Nitric Oxide/metabolism , Paraventricular Hypothalamic Nucleus/drug effects , Penile Erection/drug effects , Peptides/pharmacology , Yawning/drug effects , Animals , Apomorphine/pharmacology , Calcium/metabolism , Dizocilpine Maleate/pharmacology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Haloperidol/pharmacology , Male , Nitrates/metabolism , Oxytocin/pharmacology , Paraventricular Hypothalamic Nucleus/metabolism , Rats , Rats, Sprague-Dawley , Vasotocin/pharmacology , omega-Conotoxin GVIA
19.
Eur J Neurosci ; 10(6): 1968-74, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9753084

ABSTRACT

Male rats put in the presence of a receptive female rat that they can see, hear and smell, but cannot touch, show penile erection episodes. These non-contact erections occur concomitantly with an increase in nitric oxide production in the paraventricular nucleus of the hypothalamus, as detected by the increase in the NO2- and NO3- concentration in the paraventricular dialysate obtained from these males by in vivo microdialysis. NO2- concentration increased from 0.81+/-0.12 to 2.51+/-0.43 microM and that of NO3- from 4.50+/-0.73 to 8.31+/-2.3 microM. The NO2- increase was prevented by the nitric oxide synthase inhibitor NG-nitro-L-arginine methylester (20 microg) given unilaterally in the paraventricular nucleus, which also prevented non-contact erections. In contrast, the nitric oxide scavenger haemoglobin (20 microg) prevented the NO2- increase, but not non-contact erections; while the guanylate cyclase inhibitor methylene blue (20 microg) was ineffective on either response. NO2-and NO3- concentration was also increased in the paraventricular dialysate of male rats during in copula penile erections, that is, when sexual activity was allowed with the receptive females. As found with non-contact erections, NG-nitro-L-arginine methylester prevented NO2- increase and impaired copulatory behaviour; haemoglobin prevented NO2- increase only; and methylene blue was ineffective on either response. The present results confirm that nitric oxide is a physiological mediator of penile erection at the level of the paraventricular nucleus of the hypothalamus.


Subject(s)
Copulation/physiology , Nitric Oxide/biosynthesis , Paraventricular Hypothalamic Nucleus/metabolism , Penile Erection/physiology , Sex Characteristics , Animals , Copulation/drug effects , Enzyme Inhibitors/pharmacology , Female , Hemoglobins/pharmacology , Male , Methylene Blue/pharmacology , Nitrates/metabolism , Nitrites/metabolism , Nitroarginine/pharmacology , Paraventricular Hypothalamic Nucleus/drug effects , Rats , Rats, Sprague-Dawley , Sexual Behavior, Animal/drug effects
20.
Eur J Pharmacol ; 343(1): 1-16, 1998 Feb 05.
Article in English | MEDLINE | ID: mdl-9551709

ABSTRACT

Yawning is a phylogenetically old, stereotyped event that occurs alone or associated with stretching and/or penile erection in humans and in animals from reptiles to birds and mammals under different conditions. Although its physiological function is still unknown, yawning is under the control of several neurotransmitters and neuropeptides at the central level as this short overview of the literature on the neurochemistry of yawning shows. Among these substances, the best known are dopamine, excitatory amino acids, acetylcholine, serotonin, nitric oxide, adrenocorticotropic hormone-related peptides and oxytocin, that facilitate yawning and opioid peptides that inhibit this behavioral response. Some of the above compounds interact in the paraventricular nucleus of the hypothalamus to control yawning. This hypothalamic nucleus contains the cell bodies of oxytocinergic neurons projecting to extra-hypothalamic brain areas that play a key role in the expression of this behavioral event. When activated by dopamine, excitatory amino acids and oxytocin itself, these neurons facilitate yawning by releasing oxytocin at sites distant form the paraventricular nucleus, i.e. the hippocampus, the pons and/or the medulla oblongata. Conversely, activation of these neurons by dopamine, oxytocin or excitatory amino acids, is antagonized by opioid peptides, that, in turn, prevent the yawning response. The activation and inhibition, respectively of these oxytocinergic neurons is related to a concomitant increase and decrease, respectively, of paraventricular nitric oxide synthase activity. However, other neuronal systems in addition to the central paraventricular oxytocinergic neurons are involved in the control of yawning, since they do not seem to be involved in the expression of yawning induced by the stimulation of acetylcholine or serotoninergic receptors, nor by adrenocorticotropic hormone (ACTH) and related peptides. Nitric oxide is also involved in the induction of yawning by the latter compounds and neuronal links, for instance between dopamine and acetylcholine and dopamine and serotonin, seem to be involved in the yawning response. Finally, other neurotransmitters, i.e. gamma-aminobutyric acid (GABA) and noradrenaline, and neuropeptides, i.e. neurotensin and luteinizing hormone-releasing hormone (LH-RH), influence this behavioral response. In conclusion, in spite of some recent progress, little is known of, and more has to be done to identify, the neurochemical mechanisms underlying yawning at the central level.


Subject(s)
Brain/physiology , Yawning/physiology , Amino Acid Sequence , Animals , Humans , Male , Molecular Sequence Data , Neurotransmitter Agents/chemistry , Neurotransmitter Agents/physiology , Penile Erection/physiology , Reflex, Stretch/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...